Caris Life Sciences, Inc.

AI-generated fair value estimate for this company.

Method: 10-year two-stage FCF DCF: $124.0M TTM FCF base; 20% growth years 1-5; 10% years 6-10; 11% discount rate; 3% terminal growth; -$340.7M net cash; 282.60M shares outstanding.

Reasoning: Caris Life Sciences is a fast-growing precision-oncology molecular diagnostics company that is already free-cash-flow positive shortly after its IPO, supporting strong near-term growth assumptions; the discount rate reflects execution risk typical of a recently public, high-growth healthcare-diagnostics company.